MPI and TD2 Join in Strategic Collaboration to Provide Drug Developers a Unique Multi Biomarker Direct Path to Drug Approval

Medical Prognosis Institute A/S (MPI) – a Danish company and Translational Drug Development LLC (TD2) based in Scottsdale, Arizona, today announced a strategic collaboration offering a proprietary service that defines which initial clinical indication would most likely lead to drug approval. “This technology can dramatically increase the probability of early clinical success,” said Dr. Stephen Gately, CEO for TD2.

The use of these data is supported by strategic counselling from highly experienced translational experts focused on rapid approval. “The collaboration with TD2 is a fantastic opportunity for MPI to integrate our technology in the highly professional TD2 team,” said Peter Buhl Jensen, CEO for MPI.

“I believe there is great synergy between MPI and TD2 services. These companies share the goal of providing data and clinically relevant insight to the global pharmaceutical and biotech industries as well as leading academic institutions, to accelerate oncology drug development,” said Dr. Daniel Von Hoff, Chief Development Officer for TD2.

Efficient Data Management: One Way to Expedite the Clinical Development Proces

Debates on the safety and effectiveness of vaccines have captured the public’s attention recently. A vaccine is a preventative strategy for certain...

Read more +

The Clinical Trial Process Continues Amid COVID-19

It’s no secret that the top health concern on most Americans’ minds today is COVID-19 – a unprecedented disrupter like we’ve never seen...

Read more +

Technology Challenges and Trends in Clinical Trials

Cancer remains a leading cause of death among Americans with nearly two million newly diagnosed patients in 2018. As this trend continues, various...

Read more +

GET STARTED

Contact Us Today!

If you’re looking for an expert team to guide your trial with efficiency in mind, we can help. As the creators of the Dynamic Trial, TD2 provides start-to-finish support with trial strategy, design and execution for faster go-to-market potential.